Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience.

about

Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience.

Item

http://www.wikidata.org/entity/Q47998948

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Splenectomy vs. rituximab as a ...... a: a single center experience.

@en

Splenectomy vs. rituximab as a ...... a: a single center experience.

@nl

type

Item

label

Splenectomy vs. rituximab as a ...... a: a single center experience.

@en

Splenectomy vs. rituximab as a ...... a: a single center experience.

@nl

prefLabel

Splenectomy vs. rituximab as a ...... a: a single center experience.

@en

Splenectomy vs. rituximab as a ...... a: a single center experience.

@nl

P1476

Splenectomy vs. rituximab as a ...... ra: a single center experience

@en

P2093

Altaf Khan

http://www.w3.org/2001/XMLSchema#string

Bader S Al Qahtani

http://www.w3.org/2001/XMLSchema#string

Faris Ahmed

http://www.w3.org/2001/XMLSchema#string

Ismat Kamran

http://www.w3.org/2001/XMLSchema#string

May Anne Mendoza

http://www.w3.org/2001/XMLSchema#string

Mohammed G Al Otaibi

http://www.w3.org/2001/XMLSchema#string

Mohand Al Zughaibi

http://www.w3.org/2001/XMLSchema#string

Mohsen Al Zahrani

http://www.w3.org/2001/XMLSchema#string

Naila A Shaheen

http://www.w3.org/2001/XMLSchema#string

P2860

International consensus report on the investigation and management of primary immune thrombocytopenia

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications.

How I treat idiopathic thrombocytopenic purpura (ITP).

Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.

Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience.

Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.

P2888

s12185-017-2325-y

P304

69-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12185-017-2325-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Ahmed Al Askar

P577

2017-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28895035

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia